Measuring what matters: one standard for greener healthcare

Politico Europe · Mar 2, 2026 · Collected from RSS

Full Article

Europe’s ambition to become climate neutral by 2050 cannot succeed in healthcare unless we fix a basic problem: we do not measure sustainability in the same way across the single market. Currently, measuring Product Carbon Footprints (PCF) and Life Cycle Assessments (LCA) throughout the European Union consists of a patchwork of national methodologies and/or competing frameworks. This fragmentation is not just a technical inconvenience, it actively undermines fair procurement, increases costs, and risks unequal patient access across Europe.[1] Without a single, harmonized methodology or framework, this EU sustainability and competitiveness goal will remain challenging to achieve. Though the lack of harmonizsation may seem technical, its consequences are tangible. PCF and LCA outputs can differ widely depending on the standards and methodologies defined and endorsed by policymakers, the way they are applied by industry, or how existing international standards are interpreted and implemented across member states.[2] The result is that national authorities are effectively speaking different languages. A treatment considered more environmentally responsible in one country may be evaluated entirely differently just across the border. And without harmonized sustainability assessments for medicines, there is a risk that sustainability is given disproportionate weight compared with safety and quality, undermining high-quality medicine development. In short, fragmentation slows progress, weakens trust and, importantly, – prevents comparability. [1] In short, fragmentation slows progress, weakens trust and, importantly, – prevents comparability. In practice, the absence of a harmonized standard allows 27 different interpretations of ‘sustainability’ to coexist, which is incompatible with a functioning single market. Fortunately, PAS 2090:2025 offers what the EU has been missing: a single, science-based methodology that allows regulators, procurers, and industry to finally speak the same language. Developed with stakeholders across the healthcare and life sciences sector, PAS 2090:2025 specifies the appropriate methodology for medicines under ISO standards, aligning the playing field for everyone involved. Published by the British Standards Institution in November 2025, it reflects broad technical consensus and strong credibility. PAS 2090:2025 provides the first practical methodology for measuring the environmental performance of pharmaceuticals, establishing a common framework to support comparable environmental reporting, reduce regulatory duplication and provide policymakers with a credible basis to demonstrate progress toward climate neutrality. It also gives industry the predictability needed to invest in sustainable innovation, while ensuring that patients receive consistent assessments of a treatment’s environmental profile, regardless of where it is evaluated. Importantly, this approach reflects principles already embedded in EU policymaking. The European Health Data Space, for example, demonstrates how interoperability and standardized frameworks are essential in making cross-border data meaningful and actionable.[3] Meanwhile, the European Commission has been equally clear: harmonized technical standards and coherent sustainability rules are critical to the effective functioning of the Single Market and ensuring the free movement of goods.[4] This is a shared concern across stakeholder groups. Both the Federation of European Academies of Medicine and European Academies’ Science Advisory Council, representing Europe’s leading academies of medicine and science, have similarly highlighted the fact that common standards are essential for transparent procurement and fair competition across therapeutic categories.[5]And the innovative pharmaceutical industry, via the European Federation of Pharmaceutical Industries and Associations, has outlined both the challenges caused by the absence of harmonized standards and called for policymakers, regulators and healthcare stakeholders to endorse PAS 2090:2025 as the one, internationally accepted standard for measuring PCA and LCA in the pharmaceutical industry.[6]Europe’s leading academies of medicine and science, the European Commission, and the innovative pharmaceutical sector all point to the same conclusion: without harmonized standards, sustainability policy cannot work. At Chiesi, we support PAS 2090:2025 not because it is convenient, but because it makes our environmental performance directly comparable and therefore accountable.[2] That is why our teams have laid out ambitious, yet reachable, targets regarding the reduction of Scope 1, 2 and 3 greenhouse gas emissions. We also know that in order to reach these targets, we need to measure our actions and emissions. Measuring what matters is the foundation to making a meaningful difference.[3] Measuring what matters is the foundation to making a meaningful difference.[3] Our support for PAS 2090:2025 reflects a commitment to transparency, science-based decision-making and long-term sustainability; we use it ourselves because we believe it is the way forward — making it simple to compare products fairly, design transparent tenders, and procure with clarity. Further, industry members will be able to innovate with confidence, knowing that the life-changing efforts will be assessed with science and clear understandings. That said, no single actor can deliver alignment alone. Real progress depends on collaboration between regulators, policymakers, scientific bodies, and industry around a shared approach to measuring and comparing environmental impact. Chiesi stands ready to work with policymakers and partners across the healthcare ecosystem in favor of the adoption of PAS 2090:2025, understanding that achieving true regulatory harmonization is essential for ensuring patient access, maintaining high safety and quality standards, and fostering a globally competitive pharmaceutical industry in Europe. At the end of the day, the EU does not need another pilot program, framework, or national workaround. It needs a decision. It needs action. Europe must agree on how sustainability in healthcare is measured consistently and credibly across the single market. Measuring what matters, in the same way across Europe, is the only path to a climate-neutral, competitive, and fair European health system. Endorsing PAS 2090:2025 as the reference methodology would turn that principle into practice. Andrea Bonetti Andrea Bonetti is head of the EU office at Chiesi Farmaceutici, where he oversees the company’s public affairs strategy at European level across healthcare, sustainability and planetary health. Since opening Chiesi’s Brussels office in 2020, he has strengthened the company’s engagement with EU institutions, contributed to key policy discussions and supported initiatives to advance awareness on climate and environmental priorities in line with Chiesi’s values. He collaborates closely with cross-functional teams on the development and implementation of Chiesi’s sustainability strategy and represents the company within European and international trade associations. With more than 15 years of experience in health and environmental policy, he supports Chiesi’s external positioning and contributes to sector-wide work on environmental and sustainability frameworks. Disclaimer: POLITICAL ADVERTISEMENT The sponsor is Chiesi Farmaceutici The political advertisement is linked to advocacy on EU sustainability and Single Market policy. More information here. The above column is sponsor-generated content. To learn more about our advertising solutions, click here.